Valtecne (VLT) H2 2024 earnings summary

Executive summary

• 2024 marked a year of consolidation, with revenues at €30.4M, down 1.1% year-over-year, but a significant shift in business mix toward the medical sector, now nearly 70% of sales, up from 60% in 2023.

• EBITDA rose 6.4% to €6.2M, with margin improving to 20.8% from 18.5%, despite a 5.5% drop in value of production.

• Net profit increased 7.4% to €3.42M, and net financial position improved to €6.8M cash, up from €2.4M.

• The acquisition of 60% of Utilità Srl, a precision mechanics contract manufacturer focused on medical and aerospace, was completed in March 2025 for €6.2M, half funded by cash and half by debt.

Financial highlights

• Revenues: €30.4M (-1.1% YoY); Medical Devices up 15.1% to €21.3M, Industrial down 25.4% to €9.1M.

• EBITDA: €6.2M (+6.4% YoY); EBITDA margin: 20.8% (+2.3pp).

• EBIT: €4.44M (+2.8% YoY); Net profit: €3.42M (+7.4% YoY).

• Net financial position: €6.8M cash (vs. €2.4M in 2023).

• Capex focused on production assets, with capital invested up 8% to €9.25M.

Outlook and guidance

• 2025 expected to see slight revenue growth and further shift toward medical, offsetting cost inflation.

• Industrial segment to be further rationalized; medical remains strategic focus.

• Management sees no immediate risk from US tariffs; backlog and order book remain strong.